Amir Barmada, Joshua Sharan, Nicolas Band, Tobias Rumschlag, Arwah Yaqub, Eliana Liebman, Chadwick Prodromos
{"title":"已发表文献综述证实静脉输注间充质干细胞的安全性。","authors":"Amir Barmada, Joshua Sharan, Nicolas Band, Tobias Rumschlag, Arwah Yaqub, Eliana Liebman, Chadwick Prodromos","doi":"10.2174/1574888X17666220823092202","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mesenchymal stem cells (MSCs) have been shown to decrease inflammation and enhance healing due to their immunomodulatory properties and secretion of growth factors. Intravenous infusion is the most common delivery route of MSCs, and it is used for the treatment of a wide variety of conditions, with established efficacy.</p><p><strong>Objective: </strong>This review will analyze the safety of intravenous infusion of MSCs and determine the incidence of any possible resultant Serious Adverse Events (SAEs).</p><p><strong>Methods: </strong>Using PubMed, we searched the scientific literature to identify SAEs related to intravenous infusion of MSCs. We performed disease-specific searches and a general adverse event search.</p><p><strong>Results: </strong>A total of 70 studies were included in this review. Thousands of infusions were administered and only two SAEs were identified from the same study. The SAEs were two upper extremity thromboembolisms in patients with preexisting renal disease.</p><p><strong>Conclusion: </strong>Properly performed intravenous infusion of MSCs is very safe, with a near absence of reported serious adverse events associated with its use.</p>","PeriodicalId":10979,"journal":{"name":"Current stem cell research & therapy","volume":"18 6","pages":"779-786"},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells.\",\"authors\":\"Amir Barmada, Joshua Sharan, Nicolas Band, Tobias Rumschlag, Arwah Yaqub, Eliana Liebman, Chadwick Prodromos\",\"doi\":\"10.2174/1574888X17666220823092202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Mesenchymal stem cells (MSCs) have been shown to decrease inflammation and enhance healing due to their immunomodulatory properties and secretion of growth factors. Intravenous infusion is the most common delivery route of MSCs, and it is used for the treatment of a wide variety of conditions, with established efficacy.</p><p><strong>Objective: </strong>This review will analyze the safety of intravenous infusion of MSCs and determine the incidence of any possible resultant Serious Adverse Events (SAEs).</p><p><strong>Methods: </strong>Using PubMed, we searched the scientific literature to identify SAEs related to intravenous infusion of MSCs. We performed disease-specific searches and a general adverse event search.</p><p><strong>Results: </strong>A total of 70 studies were included in this review. Thousands of infusions were administered and only two SAEs were identified from the same study. The SAEs were two upper extremity thromboembolisms in patients with preexisting renal disease.</p><p><strong>Conclusion: </strong>Properly performed intravenous infusion of MSCs is very safe, with a near absence of reported serious adverse events associated with its use.</p>\",\"PeriodicalId\":10979,\"journal\":{\"name\":\"Current stem cell research & therapy\",\"volume\":\"18 6\",\"pages\":\"779-786\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current stem cell research & therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1574888X17666220823092202\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current stem cell research & therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1574888X17666220823092202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells.
Background: Mesenchymal stem cells (MSCs) have been shown to decrease inflammation and enhance healing due to their immunomodulatory properties and secretion of growth factors. Intravenous infusion is the most common delivery route of MSCs, and it is used for the treatment of a wide variety of conditions, with established efficacy.
Objective: This review will analyze the safety of intravenous infusion of MSCs and determine the incidence of any possible resultant Serious Adverse Events (SAEs).
Methods: Using PubMed, we searched the scientific literature to identify SAEs related to intravenous infusion of MSCs. We performed disease-specific searches and a general adverse event search.
Results: A total of 70 studies were included in this review. Thousands of infusions were administered and only two SAEs were identified from the same study. The SAEs were two upper extremity thromboembolisms in patients with preexisting renal disease.
Conclusion: Properly performed intravenous infusion of MSCs is very safe, with a near absence of reported serious adverse events associated with its use.
期刊介绍：
Current Stem Cell Research & Therapy publishes high quality frontier reviews, drug clinical trial studies and guest edited issues on all aspects of basic research on stem cells and their uses in clinical therapy. The journal is essential reading for all researchers and clinicians involved in stem cells research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
